Alnylam Pharmaceuticals (NASDAQ:ALNY) EVP Jeffrey Poulton Sells 2,206 Shares of Stock

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) EVP Jeffrey Poulton sold 2,206 shares of the company’s stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $327.65, for a total value of $722,795.90. Following the completion of the transaction, the executive vice president owned 64,273 shares in the company, valued at $21,059,048.45. This represents a 3.32% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Alnylam Pharmaceuticals Stock Performance

Shares of ALNY opened at $327.30 on Thursday. Alnylam Pharmaceuticals, Inc. has a 12-month low of $205.87 and a 12-month high of $495.55. The company has a current ratio of 2.76, a quick ratio of 2.71 and a debt-to-equity ratio of 1.28. The company has a market cap of $43.41 billion, a PE ratio of 191.40 and a beta of 0.36. The stock has a 50-day moving average price of $355.63 and a 200-day moving average price of $416.41.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings data on Thursday, February 12th. The biopharmaceutical company reported $1.25 earnings per share for the quarter, missing the consensus estimate of $1.43 by ($0.18). Alnylam Pharmaceuticals had a return on equity of 69.02% and a net margin of 6.43%.The company had revenue of $1.10 billion during the quarter, compared to the consensus estimate of $1.16 billion. During the same quarter last year, the company posted ($0.65) earnings per share. The firm’s revenue for the quarter was up 84.9% on a year-over-year basis. As a group, equities analysts forecast that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current fiscal year.

Alnylam Pharmaceuticals News Roundup

Here are the key news stories impacting Alnylam Pharmaceuticals this week:

• Positive Sentiment: Reported reimbursement win and trial progress vs. valuation — recent coverage highlights a payer/reimbursement win plus favorable trial progress that the author argues is not fully reflected in ALNY’s current valuation; this news supports upside to near-term revenue visibility and investor optimism. Alnylam Reimbursement Win And Trial Progress Versus Current Valuation Signals
• Positive Sentiment: Large orphan-drug market tailwind — a market report projects the global orphan-drug market to grow substantially through 2032, reinforcing structural demand for Alnylam’s rare-disease RNAi franchises and underpinning longer‑term revenue potential. Global Orphan Drugs Market is Anticipated to Cross USD 350 Billion by 2032 | DelveInsight
• Neutral Sentiment: Appointment of John Maraganore to another biotech board — former Alnylam CEO John M. Maraganore was named to Protego Biopharma’s board; notable industry movement but not directly material to Alnylam’s operations. Protego Biopharma Appoints John M. Maraganore, Ph.D., to Board of Directors
• Neutral Sentiment: Short-interest reporting appears to show a large increase but with reported 0 shares — the data looks like a reporting glitch (days-to-cover and short-interest ratio shown as 0.0), so it’s unlikely to be driving meaningful positioning changes today.
• Negative Sentiment: Significant insider selling by senior executives — CEO Yvonne Greenstreet and multiple EVPs sold shares on March 2–3 (aggregate disclosed proceeds roughly ~$5.6M), trimming their stakes by single-digit percentages. While insiders still hold sizable positions, the coordinated selling can create near-term negative sentiment for the stock. CEO SEC Filing

Wall Street Analysts Forecast Growth

A number of research firms recently commented on ALNY. Stifel Nicolaus increased their target price on Alnylam Pharmaceuticals from $495.00 to $508.00 and gave the company a “buy” rating in a research note on Thursday, December 11th. Bank of America reiterated a “buy” rating on shares of Alnylam Pharmaceuticals in a research report on Thursday, February 12th. Morgan Stanley decreased their price objective on Alnylam Pharmaceuticals from $495.00 to $408.00 and set an “equal weight” rating on the stock in a report on Friday, January 30th. Truist Financial cut their target price on Alnylam Pharmaceuticals from $535.00 to $530.00 and set a “buy” rating for the company in a research note on Thursday, January 8th. Finally, Wall Street Zen downgraded shares of Alnylam Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Saturday, February 14th. One research analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and five have issued a Hold rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $477.96.

Institutional Trading of Alnylam Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Vanguard Group Inc. increased its stake in shares of Alnylam Pharmaceuticals by 2.0% in the third quarter. Vanguard Group Inc. now owns 13,565,452 shares of the biopharmaceutical company’s stock worth $6,185,846,000 after buying an additional 268,313 shares during the period. Capital Research Global Investors increased its position in shares of Alnylam Pharmaceuticals by 0.4% in the third quarter. Capital Research Global Investors now owns 7,222,840 shares of the biopharmaceutical company’s stock valued at $3,293,516,000 after acquiring an additional 31,184 shares during the period. Groupama Asset Managment increased its position in shares of Alnylam Pharmaceuticals by 160.4% in the third quarter. Groupama Asset Managment now owns 4,032,082 shares of the biopharmaceutical company’s stock valued at $18,610,000 after acquiring an additional 2,483,697 shares during the period. Geode Capital Management LLC raised its stake in shares of Alnylam Pharmaceuticals by 6.1% during the fourth quarter. Geode Capital Management LLC now owns 2,650,722 shares of the biopharmaceutical company’s stock valued at $1,056,884,000 after acquiring an additional 151,480 shares during the last quarter. Finally, Norges Bank purchased a new stake in shares of Alnylam Pharmaceuticals during the fourth quarter worth about $895,816,000. Institutional investors own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.